Hangzhou Dadi Haiyang Environmental Protection
301068
HIT Welding Industry
301137
Shanghai Guangdian Electric Group
601616
Jiangxi Guoguang Commercial Chains
605188
Jiangsu Guomao Reducer
603915
CN Stock MarketDetailed Quotes
300813 TAILIN
- 17.38
- 0.000.00%
Pre-Opening Auction Jan 24 09:30 CST
2.11BMarket Cap217.25P/E (TTM)
0.00High0.00Low0lotVolume0.00Open17.38Pre Close0.00Turnover0.00%Turnover Ratio107.28P/E (Static)121.20MShares29.8052wk High3.23P/B1.32BFloat Cap10.9152wk Low20.86Limit Up76.05MShs Float66.50Historical High13.90Limit Down0.00%Amplitude10.78Historical Low0.10Dividend TTM--Avg Price0lotAsk0.58%Div YieldTTM100Lot Size0lotBid
TAILIN News
TAILIN (300813.SZ): Plans to postpone the "Cell Therapy Industrialization Equipment Manufacturing Base Project" until June 30, 2025.
Gelonghui, December 31丨TAILIN (300813.SZ) announced that the company will hold the fifth meeting of the fourth Board of Directors and the fifth meeting of the fourth Supervisory Board on December 31, 2024. The proposal concerning the extension of the fundraising for the issuance of Convertible Bonds to unspecified entities was reviewed and approved. Under the condition that the investment project主体, implementation location, investment purpose, and investment scale do not change, based on the current actual construction progress of the fundraising investment project, the fundraising for the Convertible Bonds will be allocated to the "Cell Therapy Industrialization Equipment Manufacturing Base Project" to reach the predetermined usable state.
Revenues Not Telling The Story For Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) After Shares Rise 26%
Beyond Lackluster Earnings: Potential Concerns For Zhejiang Tailin BioEngineeringLtd's (SZSE:300813) Shareholders
Tailin Biotech: Report for the third quarter of 2024
Tailin (300813.SZ): The net income in the first three quarters decreased by 46.91% year-on-year to 11.3147 million yuan.
On October 29, Gleam Health reported on Tailin (300813.SZ) in the third quarter of 2024. The company achieved revenue of 0.242 billion yuan in the first three quarters, a year-on-year increase of 19.37%; net income attributable to shareholders of the listed company was 11.3147 million yuan, a year-on-year decrease of 46.91%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 10.7105 million yuan, a year-on-year decrease of 36.75%; basic earnings per share was 0.1 yuan.
Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) CEO Da Lin Ye, the Company's Largest Shareholder Sees 17% Reduction in Holdings Value
Tailin (300813.SZ): Wholly-owned subsidiaries have obtained a total of 8 patent certificates.
Gelonghui, September 10th, Tailin Biotech (300813.SZ) announced that its wholly-owned subsidiaries Zhejiang Tailin Analytical Instrument Co., Ltd. (referred to as "Tailin Analytical Instrument"), Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science"), and Zhejiang Tailin Medical Engineering Co., Ltd. (referred to as "Tailin Medical Engineering") have recently obtained 8 patent certificates (including 2 invention patents). The specific situation is as follows:
Tailin Biotech: 2024 Semi-Annual Report Summary
Tailin Biotech: 2024 Semi-Annual Report
Tailin (300813.SZ): The net income in the first half of the year was 6.5821 million yuan, a year-on-year decrease of 71.62%.
Tailin Bio (300813.SZ) announced its semi-annual report for 2024, with a total operating revenue of 0.156 billion yuan during the reporting period, a year-on-year growth of 9.68%; net income attributable to shareholders of the listed company was 6,582.1 million yuan, a year-on-year decrease of 71.62%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 6,090.4 million yuan, a year-on-year decrease of 69.99%; basic earnings per share is 0.06 yuan.
Tailin (300813.SZ) released its performance for the first half of the year, with a net income of 6.5821 million yuan, a decrease of 71.62%.
Tailin (300813.SZ) released its 2024 interim report, with revenue of 0.156 billion...
Tailin (300813.SZ) currently does not produce in vitro diagnostic reagents.
Tailin stated on the investor interaction platform, that the current common detection methods for monkeypox virus are PCR amplification and immune detection. NC membrane can be used as the carrier of C/T line in immune chromatographic diagnostic reagents, and it is also the site of immune reaction, playing an important role in immune chromatographic technology as one of the key raw materials. The company's NC membrane series products can be used as production materials for diagnostic reagent kits based on lateral flow immune detection technology. However, the company currently does not produce in vitro diagnostic reagent kits, and there are no products available for direct detection.
Tailin (300813.SZ): Tailin's life science related products serve environmental monitoring, scientific research institutions, water conservancy, disease control and third-party testing institutions.
On July 26, Geelong News reported that Tailin's wholly-owned subsidiary, Life Science, is not only continuing to develop its microbiological testing business in the pharmaceutical industry, but also actively expanding its testing business in the water ecological field. The company is committed to becoming an excellent provider of water ecological (microorganisms + parasites + plankton) testing system solutions, and related products serve environmental monitoring, scientific research institutions, water conservancy and water affairs, disease control and third-party testing agencies. Tailin Life Science's layout in the water ecology field is also actively responding to the national call for ecological civilization construction.
Tailin (300813.SZ): The subsidiary has recently obtained 9 patent certificates and 1 software copyright certificate.
On July 22nd, Gelunhui reported that Tailin Biomedical (300813.SZ) announced that its wholly-owned subsidiary, Zhejiang Tailin Life Science Co., Ltd. (referred to as "Tailin Life Science") and Zhejiang Tailin Medical Instruments Co., Ltd. (referred to as "Tailin Medical Instruments") have jointly obtained nine patent certificates and one software copyright certificate recently. Situation of obtaining a patent certificate: Situation of obtaining a computer software copyright registration certificate:
A-share Lightning protection on July 15 | Tailin Bio: Gao De Investment intends to reduce its shareholding by no more than 1.67%; Chipbond Technology: expects to lose 0.439 billion yuan in the first half of the year.
Boji Medical Technology's controlling shareholder, the concerted action person, intends to reduce its shareholding by no more than 1.5%. Tailin Bio's shareholder, Gaode Investment, intends to reduce its shareholding by no more than 1.67%. Xilinx expects to lose 0.439 billion yuan in the first half of the year. Greentown Technology stated that the U.S. Commerce Department has initiated an anti-dumping and countervailing investigation into certain low-speed vehicles imported from China.
Tailin Biotech (300813.SZ) plans to pay 1 yuan for 10 shares to be deducted from interest on May 27
Tailin Biotech (300813.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Optimistic Investors Push Zhejiang Tailin BioEngineering Co.,Ltd (SZSE:300813) Shares Up 42% But Growth Is Lacking
Tailin Biotech (300813.SZ): The subsidiary has no products in the manufacture of bio-based materials or synthetic materials
Gelonghui, May 9丨Tailin Biology (300813.SZ) said on the investor interactive platform that its subsidiary Tailin Medical Devices currently has no products in the manufacture of bio-based materials or synthetic materials.
Tailin Biotech (300813.SZ): The company has no medical equipment related to autologous stem cell regeneration insulin transplantation
Gelonghui, May 9丨Tailin Biotech (300813.SZ) said on the investor interactive platform that the company has no medical equipment related to autologous stem cell regeneration insulin transplantation.
Tailin Biology (300813.SZ): Currently, there is no direct layout in the direction of synthetic biology
On May 7, Gelonghui | Tailin Biotech (300813.SZ) said on the investor interactive platform that the company currently has no direct layout in the direction of synthetic biology.